Two people take the exact same medication at the exact same dose. One feels fine. The other gets side effects, or the drug barely works at all. This isn’t random, and it isn’t in anyone’s head — it often comes down to how fast or slow a person’s body breaks down that specific drug, which is shaped in large part by genetics, alongside factors like age, liver and kidney function, and other medications being taken at the same time. One of the best-studied genes here is CYP2D6, an enzyme responsible for metabolizing an estimated 20 to 25% of all commonly prescribed drugs (Johnson et al., 2022). This is general biology, not medical advice — any medication questions belong with your prescribing doctor or pharmacist.
Contents
CYP2D6 and the Wide World of Everyday Medications
CYP2D6 is one of the most heavily studied drug-metabolizing genes because of how many medications pass through it, including many antidepressants, certain heart medications, and some pain relievers.
Poor, Intermediate, and Ultrarapid Metabolizers
People can be classified as poor, intermediate, normal, or ultrarapid CYP2D6 metabolizers depending on which gene variants they carry. Clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend that poor or intermediate metabolizers taking the antidepressant nortriptyline consider a dose reduction or an alternative medication, since the drug can build up to higher-than-intended levels in their system (CPIC guideline summary). On the opposite end, ultrarapid metabolizers break certain drugs down so quickly that standard doses may not reach an effective level at all.
Why This Gets Complicated
CYP2D6 genetics is only part of the picture in practice. Certain other medications can inhibit the CYP2D6 enzyme temporarily, a phenomenon called phenoconversion, which can make someone with normal genetics function like a poor metabolizer while taking that other drug — one study found patients on another CYP2D6-metabolized medication were over nine times more likely to have a mismatch between their genetic type and their actual drug response (Johnson et al., 2022). This is exactly the kind of nuance a doctor needs to weigh, not something to interpret alone.
CYP2C19 and the Clopidogrel Boxed Warning
Few examples make the real-world stakes of pharmacogenomics clearer than clopidogrel, a common blood thinner prescribed after heart attacks, stents, and strokes. Clopidogrel is a prodrug, meaning it has to be converted into its active form by an enzyme, mostly CYP2C19, before it works.
In 2010, the FDA added a boxed warning, its most serious labeling requirement, to clopidogrel after data showed that people who are CYP2C19 poor metabolizers convert less of the drug into its active form and, as a result, face higher rates of cardiovascular events after a heart attack or stent placement compared to normal metabolizers (Holmes et al., 2010). Poor metabolizer status varies notably by ancestry, affecting roughly 2% of white patients, 4% of Black patients, and up to 14% of Chinese patients in the studies the FDA reviewed. For these patients, doctors may consider an alternate antiplatelet drug that doesn’t rely on CYP2C19 for activation.
CYP2C9, VKORC1, and Personalized Warfarin Dosing
Warfarin is a classic example of a drug where the right dose can vary enormously between individuals, and two genes explain much of that variation. VKORC1 codes for the enzyme warfarin actually targets in the vitamin K cycle, while CYP2C9 metabolizes the drug itself. Together, these two genes account for a substantial share of the difference in stable warfarin dose between people, with VKORC1 contributing roughly 30% and CYP2C9 contributing up to 18%, particularly in patients of European ancestry (Johnson et al., 2017).
The FDA-approved warfarin label includes a dosing table based specifically on CYP2C9 and VKORC1 genotype combinations, and studies have shown that dosing algorithms incorporating this genetic information outperform standard clinical-factors-only approaches, especially for patients who end up needing unusually low or unusually high doses. This is one of the clearest cases where a genetic variant translates directly into a documented, FDA-recognized dosing consideration rather than a general tendency.
What Else Affects How You Respond to Medication
Genetics is one input among several. Age, kidney and liver function, body weight, pregnancy, other medications and supplements you’re taking, and even diet can all shift how a drug behaves in your system. Two people with identical genetics can still respond differently to the same prescription because of these other variables. This is why genetic information is meant to inform a conversation with a prescriber, not replace their judgment or a careful medication history.
Where Genetic Testing Fits In
If you’ve ever wondered why a medication hit you differently than expected, a medication check pharmacogenomic report can walk through genes like these and how they relate to commonly prescribed drugs. It’s meant to be a helpful reference to bring to your doctor or pharmacist, never a reason to start, stop, or adjust a medication on your own.
Frequently Asked Questions
Should I get genetic testing before starting a new medication?
That’s a conversation to have with your doctor or pharmacist. Pharmacogenomic testing is well established for certain drug-gene pairs, like clopidogrel and CYP2C19, and less established for others, so its usefulness depends on the specific medication.
Can I stop taking a medication if I think I’m a poor metabolizer?
No. Never stop or change a medication dose without talking to the prescribing doctor first, even with genetic test results in hand.
Does genetic testing explain all medication side effects?
No. Many factors beyond genetics affect drug response, including other medications, organ function, and general health. Genetics is one useful piece of the puzzle, not the whole picture.
